-+ 0.00%
-+ 0.00%
-+ 0.00%

Entera Bio plans Phase 3 registrational trial of EB613 oral osteoporosis tablet

PUBT·10/08/2026 12:03:38
Listen to the news
Entera Bio plans Phase 3 registrational trial of EB613 oral osteoporosis tablet
  • Entera Bio announced a late-breaking ASBMR 2026 poster detailing the planned Phase 3 registrational trial design for EB613, an oral osteoporosis therapy.
  • The Phase 3 design will be presented on Oct. 11, 2026, outlining how the single randomized, double-blind, placebo-controlled study will evaluate EB613.
  • Phase 2 EB613 findings were already selected for presentation at the same meeting, highlighting anabolic effects in high-fracture-risk postmenopausal osteoporosis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entera Bio Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080800PRIMZONEFULLFEED9839991) on October 08, 2026, and is solely responsible for the information contained therein.